Lexicon Pharmaceuticals Engages in December Investor Events
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), a leading biopharmaceutical company, is gearing up for an exciting December as it prepares to participate in two notable investor conferences. These events are poised to showcase its commitment to advancing innovative therapies aimed at transforming patients' lives.
Upcoming Conferences
On December 3rd, Lexicon's management will take part in a fireside chat at the distinguished Piper Sandler 37th Annual Healthcare Conference, starting at 9:00 a.m. ET. This event provides a platform for company leaders to discuss their ongoing research, pipeline advancements, and the future direction of the company.
Engagement Opportunities
Following that, on December 4th at 9:10 a.m. ET, Lexicon will also be featured at the 8th Annual Evercore Healthcare Conference. Both live events will allow investors to engage directly with company representatives, giving insight into Lexicon's innovative research and initiatives.
Innovative Research at Lexicon
Lexicon is driven by its mission to discover and develop treatments that significantly improve patients' health outcomes. Their Genome5000™ program stands out for its thorough exploration of nearly 5,000 genes, identifying over 100 key protein targets that hold considerable therapeutic potential across various diseases.
Transformative Medicines
This cutting-edge research facilitates the development of medicines that target specific proteins, paving the way for innovative therapies in areas such as heart failure, neuropathic pain, obesity, diabetes, and more. As the company pushes forward, it maintains a robust pipeline with promising drug candidates that are in various stages of clinical and preclinical development.
Company Mission and Vision
At Lexicon Pharmaceuticals, the focus remains firmly on pioneering medications that enhance the quality of life for patients. By leveraging advanced genetic research and innovative approaches, the company is setting new standards in drug discovery and development.
Investor Relations and Information
For more detailed insights about their upcoming conferences and further information on Lexicon's mission, interested parties are encouraged to visit the Company’s events page on their website. This resource serves as a gateway to connect with Lexicon’s latest endeavors and achievements.
Frequently Asked Questions
What is Lexicon Pharmaceuticals' main focus?
Lexicon Pharmaceuticals primarily focuses on pioneering innovative medicines that can transform and improve patients' lives through advanced research and development.
When are the upcoming investor conferences?
Lexicon will participate in the Piper Sandler Conference on December 3rd and the Evercore Conference on December 4th.
How can investors access the live events?
The live events can be accessed through the Events page on Lexicon Pharmaceuticals' website.
What is the Genome5000™ program?
The Genome5000™ program is Lexicon's research initiative that studies the role of nearly 5,000 genes to find significant protein targets for therapeutic development.
How can I contact Lexicon for investor inquiries?
Investor inquiries can be directed to Lisa DeFrancesco at Lexicon Pharmaceuticals via email.